Open AccessThis article is
- freely available
Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
Division of Cardiovascular Medicine and the Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
Lexington VA Medical Center, Lexington, KY 40536, USA
* Author to whom correspondence should be addressed.
Received: 6 May 2013; in revised form: 18 July 2013 / Accepted: 26 July 2013 / Published: 2 August 2013
Abstract: Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.
Keywords: platelets; thrombin; thrombosis; protease-activated receptors
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Wallace, E.L.; Smyth, S.S. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals 2013, 6, 915-928.
Wallace EL, Smyth SS. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals. 2013; 6(8):915-928.
Wallace, Eric L.; Smyth, Susan S. 2013. "Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis." Pharmaceuticals 6, no. 8: 915-928.